 |
|
|
| |
C-SWIFT: GRAZOPREVIR/ELBASVIR + SOFOSBUVIR IN CIRRHOTIC AND NONCIRRHOTIC, TREATMENT-NAIVE PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1 INFECTION, FOR DURATIONS OF 4, 6 OR 8 WEEKS AND GENOTYPE 3 INFECTION FOR DURATIONS OF 8 OR 12 WEEKS
|
| |
| |
Reported by Jules Levin
EASL 2015 April 22-26 Vienna Austria
Fred Poordad* 1, Eric Lawitz1, Julio A. Gutierrez1, Barbara Evans2, Anita Howe2, Hwa-Ping Feng2, Jerry Jing Li2, Peggy Hwang2, Michael Robertson2, Janice Wahl2, Eliav Barr2, Barbara Haber2
1The Texas Liver Institute, University of Texas Health Science Center, San Antonio, 2Merck & Co., Inc., Whitehouse Station, United States
|
| |
|
|
|
|
|
